Clinical Trial Detail

NCT ID NCT03977467
Title Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

Advanced Solid Tumor

head and neck squamous cell carcinoma

lung non-small cell carcinoma

renal cell carcinoma

lung small cell carcinoma

triple-receptor negative breast cancer

melanoma

Therapies

Atezolizumab + Carboplatin

Atezolizumab + Cisplatin

Atezolizumab

Atezolizumab + Bevacizumab + Carboplatin

Atezolizumab + Bevacizumab + Cisplatin

Age Groups: senior adult

No variant requirements are available.